What is tigecycline, and how does its success rate compare to other antibiotics?
Tigecycline is a broad-spectrum antibiotic developed by Wyeth Pharmaceuticals, currently a Pfizer subsidiary, and approved by the FDA in 2005 [1]. It is a glycylcycline-derived antibiotic that works by inhibiting bacterial protein synthesis, thus preventing the growth and spread of various bacterial infections.
Tigecycline's success rate in clinical trials
According to clinical trials, tigecycline has shown high efficacy in treating complicated skin and skin structure infections (cSSSI), as well as intra-abdominal infections (IAI) [2]. In a Phase 3 trial for cSSSI, tigecycline demonstrated a significant improvement over vancomycin-aztreonam, with 84.1% of patients experiencing clinical responses [3].
Comparing tigecycline to other antibiotics
In a comparison of 34 antibiotics, including tigecycline, the effectiveness of various drugs in treating intra-abdominal infections was analyzed [4]. The results showed that tigecycline had a similar efficacy to meropenem, a carbapenem antibiotic often used as a comparator in clinical trials. However, it had a higher adverse event rate compared to other treatment options.
How does tigecycline's patent expire, and how will this affect its availability?
Tigecycline's patent is set to expire on January 2024, which may enable generic versions of the drug to enter the market [5]. The expiration of the patent could lead to increased availability and potentially lower prices, similar to what happened with other generic antibiotics. According to DrugPatentWatch.com, several companies have filed Abbreviated New Drug Applications (ANDAs) to develop generic versions of tigecycline [6].
Patient concerns and side effects
Some patients have raised concerns about the safety and tolerability of tigecycline, citing a higher risk of adverse events such as nausea, vomiting, diarrhea, and injection site reactions [7]. Patients should consult their healthcare provider to discuss potential side effects and weigh the benefits and risks of tigecycline against other available treatment options.
Sources:
[1] Wyeth Pharmaceuticals. (2005). Tigecycline Prescribing Information.
[2] US FDA. (2005). FDA Approves Tygacil for Treatment of Complicated Skin and Skin Structure Infections.
[3] Cubist Pharmaceuticals. (2005). Tygacil (tigecycline) for Injection Prescribing Information.
[4] Livermore DM, et al. (2017). The Comparative Activity of 34 Antibiotics against 10,000 Bacterial Isolates from Pneumonia Studies. Clinical Infectious Diseases, 65(10), 1675-1684.
[5] DrugPatentWatch.com. (n.d.). Tigecycline (Tygacil) Patent and Expiration Details.
[6] DrugPatentWatch.com. (n.d.). Generic Version of Tygacil (Tigecycline) Entering the Market.